<DOC>
	<DOC>NCT01095809</DOC>
	<brief_summary>The purpose of this study is to determine whether intravitreous bevacizumab or intravitreous triamcinolone acetonide are effective and safe in the treatment of uveitic macular oedema</brief_summary>
	<brief_title>Efficacy, Safety and Tolerability of Repeated Dosis of Intravitreous Bevacizumab in Uveitic Macular Oedema</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<criteria>adult patients with uveitis or retinal vasculitis with unilateral or bilateral macular oedema with macular thickness &gt; 250 micra using OCT visual acuity at least 20/200 with stable treatment with oral prednisone at least during 3 months, either oral ciclosporin or other immunomodulator to treat intraocular inflammatory disease patient that can follow study's requirements patient who consents to participate presence of corneal or crystalline opacity preventing observation of fundus of eye patients requiring ocular surgery in next 3 months oneeyed pregnancy and child breastfeeding previous history of glaucoma on treatment woth an experimental ocular drug previous thromboembolism or receiving oral anticoagulant treatment vitrectomy patients with proved tractional macular pathology associated to macular oedema</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
</DOC>